|
|
Article: Vasogen Again Battered By Negative Data On Celacade.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Poor Celacade data sank shares of Vasogen Inc., though the company s top executive pointed to a bit of silver lining in this story.
On Monday, its stock (NASDAQ:VSGN) plummeted by 74 percent on negative Phase III data in advanced chronic heart failure patients. That clinical setback represents a delay in a regulatory filing for the technology, which is considered a device, so the shares fell $1.37 to 48 cents.
Initial results from ACCLAIM (Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy), a 2,414-patient registrational trial conducted in seven countries, showed the product did not reach the ...